If you look at figure 5 in the BRPA Jan 27 filing,

If you look at figure 5 in the BRPA Jan 27 filing, all cause mortality was a jackpot for the aviptadil trial.

But the knockout data does not happen until long after day 28.

Before day 28, the aviptadil patients are all home from the hospital while the placebo patients are still in the hospital.

At day 28 that's all you can see.

Out at day 60, Figure 5 says aviptadil reduces mortality by somewhere in the range of 70%.

So choosing all cause mortality provides a tremendous result for aviptadil according to Figure 5.

Possibly all due to SOC delaying death for critically ill patients by 30 days in Decmber compared to March.

Another strange thing about the aviptadil data is that almost every placebo patient dies. Figure 5 says aviptadil placebo mortality was either 85% or 95% on the 31 placebo patients in the aviptadil trials.

This number is way larger than what has been reported by other organizations. Were the aviptadil patients simply much, much sicker than CD12 patients? Unfortunately, the aviptadil data presented is so corrupted that its impossible to tell.